Many medical professionals and researchers have identified a shortage of endocannabinoids as a condition called endocannabinoid deficiency. It is theorised that a deficiency of these molecules, which are increasingly understood to be critical to good health and homoeostasis (balance) within humans, may lead to a variety of diseases related to the immune and nervous systems. These conditions often involve inflammation, pain and nausea, the side effects of diseases, pharmaceutical drugs and treatments like chemotherapy.
How does a knowledge of the binding affinity of particular cannabinoids to certain types of receptors within the ECS aid consumers? First, patients can become educated about how particular cannabinoids and terpenes offer therapy for targeted diseases and ailments. Those who suffer epilepsy, for example, may prefer a high-CBD, low-THC strain that reduces the incidence of seizures in both children and adults but doesn’t provide so much psychoactive effect that it interferes with one’s school, job, or family life. Common THC-to-CBD ratios of commercial products in legal states are 1:1 and 1:20, although experimentation is occurring with many ratios.
Until Cannabis is removed from Schedule I of the Controlled Substances Act, which is the US federal government’s way of officially and legally declaring it a dangerous and highly addictive drug, the necessary research to improve patient conditions for dozens of diseases and ailments will be lacking. US Congress must allow robust medical research of Cannabis, cannabinoids and terpenes, including human trials, to best serve sick patients and some of the most frail and vulnerable members of society.
What Are Cannabinoid Receptors, What Is THC, CBD Medical Treatment, Medical Marijuana Treats Post Operative Pain, How To Identify Terpenes, Marijuana Factsheets Cannabinoids, What is the Endocannabinoid System, Cannabis Treatment-Anxiety, What is Cannabinoid Deficiency, Does Cannabis Cure Crohn's?, CBC-Cannabichromene, Granny Storm Crow's List - Cancer